surmount-1 tirzepatide non-diabetic obesity trial Read now: The SURPASS-EARLY found that starting #tirzepatide early in #type2diabetes led to greater improvements in blood sugar, body weight, and waist size than intensified standard care. https://bit.ly/3RWnB8m Clinical trials of subcutaneous tirzepatide

Serious but rare complications include pancreatitis and thyroid concerns

10.1038/sj.ejcn.1602898 Eur

Payers Take Varying Approaches ICERs final policy recommendations to payers for oral semaglutide suggest that prior authorization (PA) criteria for antihyperglycemic products be based on clinical evidence, specialty society guidelines, and input from clinical experts and patient groups

Atherosclerosisan inflammatory disease

Slower Digestion: They delay stomach emptying, helping you feel full for longer periods after meals

Controindicazioni: quando non pu assumere il farmaco La tirzepatide non pu essere utilizzata in caso di allergia al principio attivo , oppure a uno qualsiasi degli eccipienti del medicinale